Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Novartis AG — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.56, while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | NVS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $168.62 |
52-Week Low | $116.45 | $113.50 |
Market Cap | — | $290.25B |
Enterprise Value | — | $330.27B |
Dividend Yield | — | 3.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
